Finch Therapeutics Group, Inc.
DelistedCIK 1733257fmd_1Y30SVWT6F1CGV1F0H2V85HYYNManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Jun 30, 2024, 18 periods
Latest annual · FY2023
Millions- Total revenues
- 0
- Operating income
- (84)
- Net income
- (75)
- Free cash flow
- (32)
Latest quarter · Q2 FY2024
Millions- Total revenues
- 0
- Operating income
- (6)
- Net income
- (5)
- Free cash flow
- (5)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- -76.0%
Finch Therapeutics Group, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | $107,000 | $861,000 | -87.6% | 10-K 2024-03-25 · proof |
| Operating income | -$83.9 million | -$115.6 million | 10-K 2024-03-25 · proof | |
| Net income | -$74.8 million | -$114.6 million | 10-K 2024-03-25 · proof | |
| Cash from operating activities | -$31.5 million | -$74.9 million | 10-K 2024-03-25 · proof | |
| Free cash flow | -$31.5 million | -$77 million | 10-K 2024-03-25 · proof | |
| Total assets | $55.4 million | $162.9 million | -66% | 10-K 2024-03-25 · proof |
| Total liabilities | $32.5 million | $67.2 million | -51.7% | 10-K 2024-03-25 · proof |
| Cash and cash equivalents | $25.1 million | $71 million | -64.6% | 10-K 2024-03-25 · proof |
- What was Finch Therapeutics Group, Inc.'s revenue in fiscal 2023?
- Finch Therapeutics Group, Inc. reported revenue of $107,000 for fiscal 2023 (the year ended Dec 31, 2023), against $861,000 the year before (-87.6%). Source: the 10-K filed with the SEC on Mar 25, 2024. SEC
- What was Finch Therapeutics Group, Inc.'s operating income in fiscal 2023?
- Finch Therapeutics Group, Inc. reported operating income of -$83.9 million for fiscal 2023 (the year ended Dec 31, 2023), against -$115.6 million the year before. Source: the 10-K filed with the SEC on Mar 25, 2024. SEC
- What was Finch Therapeutics Group, Inc.'s net income in fiscal 2023?
- Finch Therapeutics Group, Inc. reported net income of -$74.8 million for fiscal 2023 (the year ended Dec 31, 2023), against -$114.6 million the year before. Source: the 10-K filed with the SEC on Mar 25, 2024. SEC
- What was Finch Therapeutics Group, Inc.'s cash from operating activities in fiscal 2023?
- Finch Therapeutics Group, Inc. reported cash from operating activities of -$31.5 million for fiscal 2023 (the year ended Dec 31, 2023), against -$74.9 million the year before. Source: the 10-K filed with the SEC on Mar 25, 2024. SEC
- What was Finch Therapeutics Group, Inc.'s free cash flow in fiscal 2023?
- Finch Therapeutics Group, Inc. reported free cash flow of -$31.5 million for fiscal 2023 (the year ended Dec 31, 2023), against -$77 million the year before. Source: the 10-K filed with the SEC on Mar 25, 2024. SEC
- What are Finch Therapeutics Group, Inc.'s total assets?
- As of Dec 31, 2023, Finch Therapeutics Group, Inc. reported total assets of $55.4 million, against $162.9 million a year earlier (-66%). Source: the 10-K filed with the SEC on Mar 25, 2024. SEC
- What are Finch Therapeutics Group, Inc.'s total liabilities?
- As of Dec 31, 2023, Finch Therapeutics Group, Inc. reported total liabilities of $32.5 million, against $67.2 million a year earlier (-51.7%). Source: the 10-K filed with the SEC on Mar 25, 2024. SEC
- What are Finch Therapeutics Group, Inc.'s cash and cash equivalents?
- As of Dec 31, 2023, Finch Therapeutics Group, Inc. reported cash and cash equivalents of $25.1 million, against $71 million a year earlier (-64.6%). Source: the 10-K filed with the SEC on Mar 25, 2024. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1733257&period_type=annual&limit=5"Information only, not investment advice.